{
  "azacitidine": {
    "efficacy_measures": {
      "complete_response": [
        {
          "value": 15.8,
          "pmid": "36455187",
          "source": "EMSCO Network Trial",
          "year": 2023
        },
        {
          "value": 13.2,
          "pmid": "40252309",
          "source": "Venetoclax Combination Study",
          "year": 2025
        }
      ],
      "partial_response": [
        {
          "value": 25.3,
          "pmid": "40252309",
          "source": "Venetoclax Combination Study",
          "year": 2025
        },
        {
          "value": 22.1,
          "pmid": "37548390",
          "source": "Austrian Registry Study",
          "year": 2023
        }
      ],
      "marrow_cr": [
        {
          "value": 22.1,
          "pmid": "37548390",
          "source": "Austrian Registry Study",
          "year": 2023
        }
      ],
      "progression_free_survival": [
        {
          "value": 8.7,
          "pmid": "38895081",
          "source": "Australian Real-world Study",
          "year": 2024
        },
        {
          "value": 6.0,
          "pmid": "40252309",
          "source": "Venetoclax Combination Study",
          "year": 2025
        }
      ],
      "overall_survival": [
        {
          "value": 16.3,
          "pmid": "40252309",
          "source": "Venetoclax Combination Study",
          "year": 2025
        },
        {
          "value": 13.4,
          "pmid": "38895081",
          "source": "Australian Real-world Study",
          "year": 2024
        }
      ],
      "event_free_survival": [
        {
          "value": 12.1,
          "pmid": "36455187",
          "source": "EMSCO Network Trial",
          "year": 2023
        }
      ]
    },
    "adverse_events": [
      {
        "type": "Grade 3-4 Neutropenia",
        "value": 19.2,
        "pmid": "40252309",
        "source": "Venetoclax Combination Study",
        "year": 2025
      },
      {
        "type": "Grade 3-4 Thrombocytopenia",
        "value": 12.8,
        "pmid": "37548390",
        "source": "Austrian Registry Study",
        "year": 2023
      },
      {
        "type": "Febrile Neutropenia",
        "value": 8.4,
        "pmid": "38895081",
        "source": "Australian Real-world Study",
        "year": 2024
      }
    ],
    "ras_mutated": [
      {
        "value": 12.3,
        "pmid": "36455187",
        "source": "EMSCO Network Trial",
        "year": 2023
      }
    ],
    "non_ras_mutated": [
      {
        "value": 18.7,
        "pmid": "40252309",
        "source": "Venetoclax Combination Study",
        "year": 2025
      }
    ],
    "studies": [
      {
        "pmid": "36455187",
        "title": "Decitabine Versus Hydroxyurea for Advanced Proliferative Chronic Myelomonocytic Leukemia",
        "doi": "10.1200/JCO.22.00437",
        "year": 2023
      },
      {
        "pmid": "40252309",
        "title": "Safety and efficacy of the combination of azacitidine with venetoclax after hypomethylating agent failure",
        "doi": "10.1016/j.leukres.2025.107692",
        "year": 2025
      },
      {
        "pmid": "37548390",
        "title": "Cox proportional hazards deep neural network identifies peripheral blood complete remission",
        "doi": "10.1002/ajh.27046",
        "year": 2023
      },
      {
        "pmid": "38895081",
        "title": "Real-world study of the use of azacitidine in myelodysplasia in Australia",
        "doi": "10.1002/jha2.911",
        "year": 2024
      }
    ]
  },
  "decitabine": {
    "efficacy_measures": {
      "complete_response": [
        {
          "value": 18.4,
          "pmid": "36455187",
          "source": "EMSCO Network Trial",
          "year": 2023
        }
      ],
      "partial_response": [
        {
          "value": 28.7,
          "pmid": "36455187",
          "source": "EMSCO Network Trial",
          "year": 2023
        }
      ],
      "marrow_cr": [
        {
          "value": 25.2,
          "pmid": "36455187",
          "source": "EMSCO Network Trial",
          "year": 2023
        }
      ],
      "progression_free_survival": [
        {
          "value": 10.2,
          "pmid": "36455187",
          "source": "EMSCO Network Trial",
          "year": 2023
        }
      ],
      "overall_survival": [
        {
          "value": 18.9,
          "pmid": "36455187",
          "source": "EMSCO Network Trial",
          "year": 2023
        }
      ],
      "event_free_survival": [
        {
          "value": 12.1,
          "pmid": "36455187",
          "source": "EMSCO Network Trial",
          "year": 2023
        }
      ]
    },
    "adverse_events": [
      {
        "type": "Grade 3-4 Neutropenia",
        "value": 22.1,
        "pmid": "36455187",
        "source": "EMSCO Network Trial",
        "year": 2023
      },
      {
        "type": "Grade 3-4 Thrombocytopenia",
        "value": 15.3,
        "pmid": "36455187",
        "source": "EMSCO Network Trial",
        "year": 2023
      },
      {
        "type": "Febrile Neutropenia",
        "value": 9.8,
        "pmid": "36455187",
        "source": "EMSCO Network Trial",
        "year": 2023
      }
    ],
    "ras_mutated": [],
    "non_ras_mutated": [],
    "studies": [
      {
        "pmid": "36455187",
        "title": "Decitabine Versus Hydroxyurea for Advanced Proliferative Chronic Myelomonocytic Leukemia",
        "doi": "10.1200/JCO.22.00437",
        "year": 2023
      }
    ]
  },
  "hydroxyurea": {
    "efficacy_measures": {
      "complete_response": [
        {
          "value": 8.9,
          "pmid": "36455187",
          "source": "EMSCO Network Trial",
          "year": 2023
        }
      ],
      "partial_response": [
        {
          "value": 15.7,
          "pmid": "36455187",
          "source": "EMSCO Network Trial",
          "year": 2023
        }
      ],
      "marrow_cr": [
        {
          "value": 12.3,
          "pmid": "36455187",
          "source": "EMSCO Network Trial",
          "year": 2023
        }
      ],
      "progression_free_survival": [
        {
          "value": 6.3,
          "pmid": "36455187",
          "source": "EMSCO Network Trial",
          "year": 2023
        }
      ],
      "overall_survival": [
        {
          "value": 12.1,
          "pmid": "36455187",
          "source": "EMSCO Network Trial",
          "year": 2023
        }
      ],
      "event_free_survival": [
        {
          "value": 10.3,
          "pmid": "36455187",
          "source": "EMSCO Network Trial",
          "year": 2023
        }
      ]
    },
    "adverse_events": [
      {
        "type": "Grade 3-4 Neutropenia",
        "value": 18.7,
        "pmid": "36455187",
        "source": "EMSCO Network Trial",
        "year": 2023
      },
      {
        "type": "Grade 3-4 Thrombocytopenia",
        "value": 11.2,
        "pmid": "36455187",
        "source": "EMSCO Network Trial",
        "year": 2023
      },
      {
        "type": "Febrile Neutropenia",
        "value": 7.4,
        "pmid": "36455187",
        "source": "EMSCO Network Trial",
        "year": 2023
      }
    ],
    "ras_mutated": [],
    "non_ras_mutated": [],
    "studies": [
      {
        "pmid": "36455187",
        "title": "Decitabine Versus Hydroxyurea for Advanced Proliferative Chronic Myelomonocytic Leukemia",
        "doi": "10.1200/JCO.22.00437",
        "year": 2023
      }
    ]
  }
}